This open-label prospective study (n=25) evaluated esketamine nasal spray (ESK-NS) treatment for treatment-resistant depression (TRD). Over three months, patients reported early and sustained improvements in depression, anhedonia, and suicidality, while clinicians detected improvements that varied at different time points.
- Published
- Journal
- Brain Sciences
- Authors
- Pepe, M., Bartolucci, G., Marcelli, I., Pesaresi, F., Brugnami, A., Cas, R., Fischetti, A., Grisoni, F., Mazza, M., Camardese, G., Nicola, M. D., Sani, G.